Literature DB >> 26818526

Neurodegeneration Triggers Peripheral Immune Cell Recruitment into the Forebrain.

Miriam Scheld1, Bernhard Josef Rüther1, René Große-Veldmann1, Kim Ohl2, Klaus Tenbrock2, Daniela Dreymüller3, Petra Fallier-Becker4, Adib Zendedel1, Cordian Beyer1, Tim Clarner1, Markus Kipp5.   

Abstract

Brain-intrinsic degenerative cascades have been proposed to be an initial factor driving lesion formation in multiple sclerosis (MS). Here, we identify neurodegeneration as a potent trigger for peripheral immune cell recruitment into the mouse forebrain. Female C57BL/6 mice were fed cuprizone for 3 weeks, followed by a period of 2 weeks on normal chow to induce the formation of lesion foci in the forebrain. Subsequent immunization with myelin oligodendrocyte glycoprotein 35-55 peptide, which induces myelin autoreactive T cells in the periphery, resulted in massive immune cell recruitment into the affected forebrain. Additional adoptive transfer experiments together with flow cytometry analysis underline the importance of brain-derived signals for immune cell recruitment. This study clearly illustrates the significance of brain-intrinsic degenerative cascades for immune cell recruitment and MS lesion formation. Additional studies have to address the signaling cascades and mechanistic processes that form the top-down communication between the affected brain area, neurovascular unit, and peripheral immune cells. SIGNIFICANCE STATEMENT: We identify neurodegeneration as a potent trigger for peripheral immune cell recruitment into the forebrain. Thus, immune cell recruitment might be a second step during the formation of new inflammatory lesions in multiple sclerosis. A better understanding of factors regulating neurodegeneration-induced immune cell recruitment will pave the way for the development of novel therapeutic treatment strategies.
Copyright © 2016 the authors 0270-6474/16/361410-06$15.00/0.

Entities:  

Keywords:  cytodegeneration; invasion; trigger

Mesh:

Substances:

Year:  2016        PMID: 26818526      PMCID: PMC6604825          DOI: 10.1523/JNEUROSCI.2456-15.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  27 in total

1.  Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases.

Authors:  Fahmy Aboul-Enein; Helmut Rauschka; Barbara Kornek; Christine Stadelmann; Andreas Stefferl; Wolfgang Brück; Claudia Lucchinetti; Manfred Schmidbauer; Kurt Jellinger; Hans Lassmann
Journal:  J Neuropathol Exp Neurol       Date:  2003-01       Impact factor: 3.685

2.  Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion.

Authors:  Michael H Barnett; John W Prineas
Journal:  Ann Neurol       Date:  2004-04       Impact factor: 10.422

3.  Demyelination caused by the copper chelator cuprizone halts T cell mediated autoimmune neuroinflammation.

Authors:  Paula Maña; Susan A Fordham; Maria A Staykova; Manuel Correcha; Diego Silva; David O Willenborg; David Liñares
Journal:  J Neuroimmunol       Date:  2009-04-03       Impact factor: 3.478

4.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

5.  Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions.

Authors:  C J De Groot; E Bergers; W Kamphorst; R Ravid; C H Polman; F Barkhof; P van der Valk
Journal:  Brain       Date:  2001-08       Impact factor: 13.501

6.  Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group.

Authors:  G P Rice; M Filippi; G Comi
Journal:  Neurology       Date:  2000-03-14       Impact factor: 9.910

7.  The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.

Authors:  M Kremenchutzky; G P A Rice; J Baskerville; D M Wingerchuk; G C Ebers
Journal:  Brain       Date:  2006-01-09       Impact factor: 13.501

8.  MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals.

Authors:  Francois Cotton; Howard L Weiner; Ferenc A Jolesz; Charles R G Guttmann
Journal:  Neurology       Date:  2003-02-25       Impact factor: 9.910

Review 9.  CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease?

Authors:  Kavon Rezai-Zadeh; David Gate; Terrence Town
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-11       Impact factor: 4.147

10.  Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.

Authors:  A J Coles; M G Wing; P Molyneux; A Paolillo; C M Davie; G Hale; D Miller; H Waldmann; A Compston
Journal:  Ann Neurol       Date:  1999-09       Impact factor: 10.422

View more
  26 in total

1.  Thalamus Degeneration and Inflammation in Two Distinct Multiple Sclerosis Animal Models.

Authors:  Nina Wagenknecht; Birte Becker; Miriam Scheld; Cordian Beyer; Tim Clarner; Tanja Hochstrasser; Markus Kipp
Journal:  J Mol Neurosci       Date:  2016-08-04       Impact factor: 3.444

2.  Toll-Like Receptor 2-Mediated Glial Cell Activation in a Mouse Model of Cuprizone-Induced Demyelination.

Authors:  Stefan Esser; Larissa Göpfrich; Kai Bihler; Eugenia Kress; Stella Nyamoya; Simone C Tauber; Tim Clarner; Matthias B Stope; Thomas Pufe; Markus Kipp; Lars-Ove Brandenburg
Journal:  Mol Neurobiol       Date:  2017-12-29       Impact factor: 5.590

3.  Cuprizone-Containing Pellets Are Less Potent to Induce Consistent Demyelination in the Corpus Callosum of C57BL/6 Mice.

Authors:  Tanja Hochstrasser; Gianna Lisa Exner; Stella Nyamoya; Christoph Schmitz; Markus Kipp
Journal:  J Mol Neurosci       Date:  2017-02-25       Impact factor: 3.444

4.  Brain Volume Loss, Astrocyte Reduction, and Inflammation in Anorexia Nervosa.

Authors:  Jochen Seitz; Stefanie Trinh; Vanessa Kogel; Cordian Beyer
Journal:  Adv Neurobiol       Date:  2021

5.  Siponimod ameliorates metabolic oligodendrocyte injury via the sphingosine-1 phosphate receptor 5.

Authors:  Newshan Behrangi; Leo Heinig; Linda Frintrop; Emily Santrau; Jens Kurth; Bernd Krause; Dimitrinka Atanasova; Tim Clarner; Athanassios Fragoulis; Markus Joksch; Henrik Rudolf; Sven G Meuth; Sarah Joost; Markus Kipp
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-26       Impact factor: 12.779

6.  Biochemically altered myelin triggers autoimmune demyelination.

Authors:  Andrew V Caprariello; James A Rogers; Megan L Morgan; Vahid Hoghooghi; Jason R Plemel; Adam Koebel; Shigeki Tsutsui; Jeffrey F Dunn; Lakshmi P Kotra; Shalina S Ousman; V Wee Yong; Peter K Stys
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-04       Impact factor: 11.205

7.  Nrf2 deficiency increases oligodendrocyte loss, demyelination, neuroinflammation and axonal damage in an MS animal model.

Authors:  Anna Nellessen; Stella Nyamoya; Adib Zendedel; Alexander Slowik; Christoph Wruck; Cordian Beyer; Athanassios Fragoulis; Tim Clarner
Journal:  Metab Brain Dis       Date:  2019-09-16       Impact factor: 3.584

Review 8.  Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy-Kynurenines Are Important Players.

Authors:  Dániel Sandi; Zsanett Fricska-Nagy; Krisztina Bencsik; László Vécsei
Journal:  Molecules       Date:  2021-06-05       Impact factor: 4.411

Review 9.  Multiple sclerosis: experimental models and reality.

Authors:  Hans Lassmann; Monika Bradl
Journal:  Acta Neuropathol       Date:  2016-10-20       Impact factor: 17.088

10.  Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945.

Authors:  Nicolau Beckmann; Elisa Giorgetti; Anna Neuhaus; Stefan Zurbruegg; Nathalie Accart; Paul Smith; Julien Perdoux; Ludovic Perrot; Mark Nash; Sandrine Desrayaud; Peter Wipfli; Wilfried Frieauff; Derya R Shimshek
Journal:  Acta Neuropathol Commun       Date:  2018-02-15       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.